

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

11

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/550,173	04/14/00	OOE	N 2185-0424-SP

HM22/0103

BIRCH STEWART KOLASCH & BIRCH LLP
P O BOX 747
FALLS CHURCH VA 22040-0747

EXAMINER

DAVIS, K

ART UNIT

PAPER NUMBER

1636

6

DATE MAILED:

01/03/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.

09/550,173

Applicant(s)

OOE ET AL.

Examiner

Katharine F. Davis

Art Unit

1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on April 14, 2000 and August 14 and 28, 2000.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-16 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-16 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claims _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. & 119(e).

Attachment(s)

- 15) ☒ Notice of References Cited (PTO-892)
- 16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 17) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 3, 5.
- 18) ☐ Interview Summary (PTO-413) Paper No(s) _____.
- 19) ☐ Notice of Informal Patent Application (PTO-152)
- 20) ☒ Other: Notice To Comply.

DETAILED ACTION

This Office Action is in response to the application filed on April 14, 2000 and to the Information Disclosure Statements filed on August 14 and August 28, 2000. Claims 1-16 are pending in the instant application.

Specification

The abstract of the disclosure is objected to because it contains more than the one required paragraph. Correction is required. See MPEP § 608.01(b).

The disclosure is objected to because of the following informality: the use of the term "allylhydrocarbon receptor". The "allylhydrocarbon receptor" is not a known term in the art for a receptor of dioxin. For examination purposes the correct term is assumed to be "aryl hydrocarbon receptor". Appropriate correction is required.

The specification contains nucleotide and/or amino acid sequences (on pages 19, 43, 44, 46, 47, 50, 51, 64, 65, 69, 70, 72, 73, 79 and 81-85) that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the

Art Unit: 1636

reason set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. Applicant must provide a paper copy and a computer readable copy of the Sequence Listing and a statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). A full response to this Office action must include a complete response to the requirement for a new Sequence Listing.

Claim Objections

Claim 14 is objected to because of the following informality: the recitation of the phrase "naturally having". This phrase is grammatically incorrect. Appropriate correction is required.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claim 10 is rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex*

parte Dunki, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd. v. Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 10 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 10 provides for the use of an animal cell for evaluating an agonist activity or an antagonist activity of a chemical substance over the transcription promoting ability of a ligand-responsive transcription control factor, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claims 1-16 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1, 2, 9 and 14 are indefinite in the recitation of the phrase “substantially consists of”. The definition of the phrase on pages 20-21 of the instant specification is not sufficient to clearly define the metes and bounds of the claims.

Claims 3, 4 and 9-13 are indefinite in the recitation of the term “allylhydrocarbon receptor.” The “allylhydrocarbon receptor” is not a known term in the art for a receptor of dioxin. For examination purposes the correct term is assumed to be “aryl hydrocarbon receptor”.

Claim 9 recites the limitation "said responsive transcription control factor" in lines 11-12. There is insufficient antecedent basis for this limitation in the claim.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-3, 5-8 and 10-15 are rejected under 35 U.S.C. 102(b) as being anticipated by Evans *et al.* (US Patent 5,298,429: IDS reference). Evans *et al.* teaches a mammalian cell containing non-endogenous DNA which expresses a hormone receptor (said receptor can be an intranuclear hormone receptor, estrogen receptor, androgen receptor and/or a thyroid hormone receptor) and a DNA sequence which expresses a hormone response element operatively linked to a reporter gene sequence. The test cell of Evans *et al.* is made by introducing into said cell

Art Unit: 1636

plasmids which contain the non-endogenous DNA sequences and selection marker gene sequences for propagation of the plasmids in the test cells. The non-endogenous DNA sequences are eukaryotic sequences which are known in the art to have TATA box promoter sequences. The test cells are employed in a method for determining whether a substance is a hormone receptor agonist or a hormone receptor antagonist. The test cells are cultured in the presence of the substance and the expression of the reporter gene is monitored to assess transcription activity. The test cells with reagents for making and using the test cells can be contained in a kit. The elements in claims 1, 2, 5-8 and 10-15 read on the test cells and bioassay of Evans *et al.* (see entire document).

Claims 1-5 and 9-15 are rejected under 35 U.S.C. 102(b) as being anticipated by Bradfield *et al.* (US Patent 5,650,283; IDS reference). The test cells and methods of Bradfield *et al.* are akin to those of Evans *et al.* with the exception that Bradfield *et al.* teaches a test cell which is modified to express the intranuclear dioxin receptor (Ah receptor or aryl hydrocarbon receptor) and its dimerization partner, the Arnt receptor. The elements in claims 1-5 and 9-15 read on the test cells and bioassay of Bradfield *et al.* (see entire document).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claim 16 is rejected under 35 U.S.C. 103(a) as being unpatentable over Evans *et al.* (US Patent 5,298,429; IDS reference). Claim 16 requires that the plasmid encoding the receptor gene have a different selectable marker from the plasmid encoding the reporter gene. Evans *et al.* teaches cotransfection of both plasmids into the test cells however does not specifically teach that the cotransfected plasmids have different selection markers. It is well known in the art that when carrying out a cotransfection protocol it is advantageous to use different selection markers for each plasmid in order to be sure that each plasmid was successfully taken up by the cell. One of skill in the art would be motivated to use different selection markers as a control method in cotransfection protocols. Therefore it would have been obvious to a person of ordinary skill in


Art Unit: 1636

the art at the time that the instant invention was made to use different selection marker genes for each plasmid when carrying out cotransfection protocols.

Conclusion

Claims 1-16 are rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Katharine F. Davis whose telephone number is (703) 605-1195. The examiner can normally be reached on Monday-Friday (8:30am-5:00pm). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Richard Schwartz can be reached on (703) 308-1133. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 305-1935 for After Final communications. Any inquiry concerning the formalities of this application should be directed to Patent Analyst Dianiece Jacobs whose telephone number is (703) 305-3388. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Katharine F. Davis/KFD
January 2, 2001


ROBERT A. SCHWARTZMAN
PRIMARY EXAMINER

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,JPAB,EPAB,DWPI,TDBD	111 and hormone recepto\$	61	<u>L12</u>
USPT,JPAB,EPAB,DWPI,TDBD	evans-ronald-m.in.	110	<u>L11</u>
USPT,JPAB,EPAB,DWPI,TDBD	evans-ronald.in.	5	<u>L10</u>
USPT,JPAB,EPAB,DWPI,TDBD	18 same assay	21	<u>L9</u>
USPT,JPAB,EPAB,DWPI,TDBD	estrogen recepto\$ same agonist	156	<u>L8</u>
USPT,JPAB,EPAB,DWPI,TDBD	hormone recepto\$ agonist	30	<u>L7</u>
USPT,JPAB,EPAB,DWPI,TDBD	11 same hydrocarbon recepto\$	0	<u>L6</u>
USPT,JPAB,EPAB,DWPI,TDBD	arnt	256	<u>L5</u>
USPT,JPAB,EPAB,DWPI,TDBD	13 same hydrocarbon recepto\$	19	<u>L4</u>
USPT,JPAB,EPAB,DWPI,TDBD	arnt	256	<u>L3</u>
USPT,JPAB,EPAB,DWPI,TDBD	arnt recepto\$	1	<u>L2</u>
USPT,JPAB,EPAB,DWPI,TDBD	allylhydrocarbon recepto\$	0	<u>L1</u>

Attachment
to paper # 6
FOAM

[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)

Search Results -

Term	Documents
HORMONE.DWPI,TDBD,EPAB,JPAB,USPT.	34536
HORMONES.DWPI,TDBD,EPAB,JPAB,USPT.	26068
RECEPTOS	0
RECEPTO.DWPI,TDBD,EPAB,JPAB,USPT.	51
RECEPTOC.DWPI,TDBD,EPAB,JPAB,USPT.	1
RECEPTOCLE.DWPI,TDBD,EPAB,JPAB,USPT.	1
RECEPTOD.DWPI,TDBD,EPAB,JPAB,USPT.	1
RECEPTODE.DWPI,TDBD,EPAB,JPAB,USPT.	1
RECEPTOE.DWPI,TDBD,EPAB,JPAB,USPT.	1
RECEPTOE-BINDING.DWPI,TDBD,EPAB,JPAB,USPT.	1
(L11 AND HORMONE RECEPTOS) USPT,JPAB,EPAB,DWPI,TDBD.	61

There are more results than shown above. [Click here to view the entire set.](#)

Database:

US Patents Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search:

l11 and hormone receptoS

[Clear](#)

Search History

Today's Date: 12/29/2000

Status: Path 1 of [Dialog Information Services via Modem]

Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)
Trying 3106900061...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

***** HHHHHHHH SSSSSSS?

Status: Signing onto Dialog

ENTER PASSWORD:

***** HHHHHHHH SSSSSSS? *****

Welcome to DIALOG

Status: Connected

Dialog level 00.12.12D

Last logoff: 12dec00 18:34:44

Logon file001 29dec00 15:31:05

*** ANNOUNCEMENT ***

NEW FILE RELEASED

***Prous Science Daily Essentials (Files 458, 459)

***WIPO/PCT Patents Fulltext (File 349)

UPDATING RESUMED

***Extel News Cards from Primark (File 501)

***TFSD Ownership Database (File 540)

RELOADED

***Kompass USA (File 584)

***Kompass Canada (File 594)

***PsyncINFO (File 11)

FILES REMOVED

***EconBase (File 565)

***Unlisted Drugs (File 140)

>>>Get immediate news with Dialog's First Release
news service. First Release updates major newswire
databases within 15 minutes of transmission over the
wire. First Release provides full Dialog searchability
and full-text features. To search First Release files in
OneSearch simply BEGIN FIRST for coverage from Dialog's
broad spectrum of news wires.

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
>>> of new databases, price changes, etc. <<<

KWIC is set to 50.

HIGHLIGHT set on as '*'

File 1:ERIC 1966-2000/Dec 05
(c) format only 2000 The Dialog Corporation

Set Items Description

--- -----

?b 155, 5

29dec00 15:31:24 User259980 Session D61.1

\$0.41 0.117 DialUnits File1

\$0.41 Estimated cost File1

\$0.02 TYMNET

\$0.43 Estimated cost this search

\$0.43 Estimated total session cost 0.117 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1966-2000/Dec W4

(c) format only 2000 Dialog Corporation
 *File 155: For information on updating, changes to the file, and
 check tags information please see Help News155.
 File 5:Biosis Previews(R) 1969-2000/Dec W5
 (c) 2000 BIOSIS

Set	Items	Description
29dec00	15:31:35	User259980 Session D61.2
\$0.10	0.030	DialUnits File155
\$0.10		Estimated cost File155
\$0.17	0.030	DialUnits File5
\$0.17		Estimated cost File5
		OneSearch, 2 files, 0.060 DialUnits FileOS
\$0.01		TYMNET
\$0.28		Estimated cost this search
\$0.71		Estimated total session cost 0.177 DialUnits

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
 (c) 1998 Inst for Sci Info

Set	Items	Description
29dec00	15:31:35	User259980 Session D61.2

?e au=ooe, norihisa

Ref	Items	Index-term
E1	16	AU=OOE T
E2	1	AU=OOE Y
E3	0	*AU=OOE, NORIHISA
E4	1	AU=OOEDA M
E5	1	AU=OOEDA T
E6	1	AU=OOEDA Y
E7	1	AU=OORBY WA
E8	1	AU=OOFUSA H
E9	1	AU=OOGA K
E10	1	AU=OOGA T
E11	1	AU=OOGA Y
E12	1	AU=OOGAI M

Enter P or PAGE for more

?p

Ref	Items	Index-term
E13	2	AU=OOGAI T
E14	2	AU=OOGAITO M
E15	11	AU=OOGAKI C
E16	1	AU=OOGAKI I
E17	3	AU=OOGAKI K
E18	4	AU=OOGAKI M
E19	1	AU=OOGAKI S
E20	1	AU=OOGAKICHINO M
E21	1	AU=OOGAMA Y
E22	1	AU=OOGAME T
E23	1	AU=OOGANE Y
E24	1	AU=OOGAWARA Y

Enter P or PAGE for more

?e au=matsunaga, haruyuki

Ref	Items	Index-term
E1	6	AU=MATSUNAGA TO
E2	132	AU=MATSUNAGA Y
E3	0	*AU=MATSUNAGA, HARUYUKI
E4	1	AU=MATSUNAGAI K
E5	1	AU=MATSUNAKA H
E6	5	AU=MATSUNAKA M
E7	3	AU=MATSUNAKA N
E8	11	AU=MATSUNAKA S
E9	95	AU=MATSUNAMI H

E10 23 AU=MATSUNAMI K
E11 3 AU=MATSUNAMI M
E12 60 AU=MATSUNAMI N

Enter P or PAGE for more
?s allylhydrocarbon recepto?
S1 0 ALLYLHYDROCARBON RECEPTO?
?s allylhydrocarbon recepto?
S2 0 ALYLHYDROCARBON RECEPTO?
?s arnt
S3 1 ARNT
?t/9/all

3/9/1
DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

08491716 Genuine Article#: L1245 Number of References: 0
(NO REFS KEYED)
Title: GENETIC-ENGINEERING, THE ENZYMOLOGISTS NEW TOOL - EXAMPLE -
METHIONYL-*ARNT* SYNTHETASE
Author(s): DARDEL F; HIREL PH; MECHULAM Y; MELLOTT P
Corporate Source: ECOLE POLYTECH, BIOCHIM LAB, CNRS/F-91128
PALAISEAU//FRANCE/
Journal: BIOFUTUR, 1987, N62, P83-86
Language: FRENCH Document Type: ARTICLE
Geographic Location: FRANCE
Subfile: SciSearch; CC AGR1--Current Contents, Agriculture, Biology &
Environmental Sciences
?s hormone receptor?
S4 1847 HORMONE RECEPTOR?
?s s4 and agonist
1847 S4
13626 AGONIST
S5 52 S4 AND AGONIST
?s s5 and estrogen
52 S5
18245 ESTROGEN
S6 14 S5 AND ESTROGEN
?rd
...completed examining records
S7 14 RD (unique items)
?t/3/all

7/3/1
DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

08890068 Genuine Article#: P1157 No. References: 34
Title: EFFECTS OF 2 DIFFERENT MEDICAL TREATMENTS ON DIHYDROTESTOSTERONE
CONTENT AND ANDROGEN RECEPTORS IN HUMAN BENIGN PROSTATIC HYPERPLASIA
Author(s): PETRANGELI E; SCIARRA F; DISILVERIO F; TOSCANO V; LUBRANO C;
CONTI C; CONCOLINO G
Corporate Source: UNIV ROME LA SAPIENZA, IST CLIN MED 5/I-00185 ROME//ITALY/
; UNIV ROME LA SAPIENZA, IST PATOL UROL/I-00185 ROME//ITALY/
Journal: JOURNAL OF STEROID BIOCHEMISTRY, 1988, V30, N1-6, P395-399
Language: ENGLISH Document Type: ARTICLE

7/3/2
DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

08763214 Genuine Article#: N2063 No. References: 340
Title: CANCER OF THE PROSTATE - ENDOCRINE FACTORS
Author(s): GRIFFITHS K; DAVIES P; EATON CL; HARPER ME; PEELING WB; TURKES
AO; TURKES A; WILSON DW; PIERREPOINT CG
Corporate Source: UNIV WALES COLL MED, TENOVUS INST CANC RES/CARDIFF CF4
4XX/S GLAM/WALES/
Journal: OXFORD REVIEWS OF REPRODUCTIVE BIOLOGY, 1987, V9, P192-259
Language: ENGLISH Document Type: REVIEW, BIBLIOGRAPHY

7/3/3

DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

08697518 Genuine Article#: M8229 No. References: 40
Title: STEROID BINDING AT SIGMA-RECEPTORS SUGGESTS A LINK BETWEEN
ENDOCRINE, NERVOUS, AND IMMUNE-SYSTEMS
Author(s): SU TP; LONDON ED; JAFFE JH
Corporate Source: NIDA,ADDICT RES CTR,POB 5180/BALTIMORE//MD/21224
Journal: SCIENCE, 1988, V240, N4849, P219-221
Language: ENGLISH Document Type: ARTICLE

7/3/4

DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

08636885 Genuine Article#: M3026 No. References: 55
Title: EVALUATION OF ESTRADIOL BINDING IN HUMAN BENIGN PROSTATIC
HYPERPLASIA
Author(s): GANESAN S; BASHIRELAHI N; YOUNG JD
Corporate Source: UNIV MARYLAND,SCH DENT,DEPT BIOCHEM/BALTIMORE//MD/21201;
UNIV MARYLAND,SCH MED,DEPT SURG,DIV UROL/BALTIMORE//MD/21201
Journal: JOURNAL OF CLINICAL LABORATORY ANALYSIS, 1988, V2, N1, P25-34
Language: ENGLISH Document Type: ARTICLE

7/3/5

DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

08623514 Genuine Article#: M1851 No. References: 217
Title: STEROID EFFECTS ON EXCITABLE-MEMBRANES
Author(s): ERULKAR SD; WETZEL DM
Corporate Source: UNIV PENN,SCH MED,DEPT PHARMACOL/PHILADELPHIA//PA/19104
Journal: CURRENT TOPICS IN MEMBRANES AND TRANSPORT, 1987, V31, P141-190
Language: ENGLISH Document Type: ARTICLE

7/3/6

DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

08503625 Genuine Article#: L3343 No. References: 41
Title: PITUITARY-TESTICULAR FUNCTION OF PROSTATIC-CANCER PATIENTS DURING
TREATMENT WITH A GONADOTROPIN-RELEASING HORMONE *AGONIST* ANALOG .2.
ENDOCRINOLOGY AND HISTOLOGY OF THE TESTIS
Author(s): HUHTANIEMI I; NIKULA H; PARVINEN M; RANNIKKO S
Corporate Source: UNIV TURKU,DEPT PHYSIOL,KIINAMYLlynkatu 10/SF-20520 TURKU
52//FINLAND//; UNIV TURKU,DEPT ANAT/SF-20520 TURKU 52//FINLAND//; UNIV
HELSINKI,DEPT CLIN CHEM/SF-00100 HELSINKI 10//FINLAND//; UNIV
HELSINKI,DEPT SURG 2/SF-00100 HELSINKI 10//FINLAND/
Journal: JOURNAL OF ANDROLOGY, 1987, V8, N6, P363-373
Language: ENGLISH Document Type: ARTICLE

7/3/7

DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

08055196 Genuine Article#: H0329 No. References: 154
Title: HORMONE AGONISTS AND ANTAGONISTS IN THE TREATMENT OF HORMONE
SENSITIVE BREAST AND PROSTATE-CANCER
Author(s): NICHOLSON RI; WALKER KJ; DAVIES P
Corporate Source: UNIV WALES COLL MED,TENOVUS INST CANC RES,HEATHPK/CARDIFF
CF4 4XX/S GLAM/WALES/
Journal: CANCER SURVEYS, 1986, V5, N3, P463-486
Language: ENGLISH Document Type: REVIEW, BIBLIOGRAPHY

7/3/8
DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

08031307 Genuine Article#: G8922 No. References: 34
Title: RELATIONSHIP BETWEEN ANDROGEN RECEPTOR-BINDING ACTIVITY IN
HUMAN-PROSTATE CANCER AND CLINICAL-RESPONSE TO ENDOCRINE THERAPY
Author(s): BENSON RC; GORMAN PA; OBRIEN PC; HOLICKY EL; VENEZIALE CM
Corporate Source: MAYO CLIN & MAYO FDN, DEPT UROL, 200 1ST ST
SW/ROCHESTER//MN/55905; MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOLEC
BIOL/ROCHESTER//MN/55905; MAYO CLIN & MAYO FDN, MED RES STAT
SECT/ROCHESTER//MN/55905
Journal: CANCER, 1987, V59, N9, P1599-1606
Language: ENGLISH Document Type: ARTICLE

7/3/9
DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

08010634 Genuine Article#: G7629 No. References: 23
Title: CHARACTERIZATION OF ANDROGEN RECEPTORS IN A TRANSPLANTABLE HUMAN
PROSTATIC ADENOCARCINOMA (PC-82)
Author(s): BRINKMANN AO; BOLT J; VANSTEENBRUGGE GJ; KUIPER GGJM; DEBOER W;
MULDER E
Corporate Source: ERASMUS UNIV, DEPT BIOCHEM 2, POB 1738/3000 DR
ROTTERDAM//NETHERLANDS//; ERASMUS UNIV, DEPT UROL/3000 DR
ROTTERDAM//NETHERLANDS/
Journal: PROSTATE, 1987, V10, N2, P133-143
Language: ENGLISH Document Type: ARTICLE

7/3/10
DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.
07913537 Genuine Article#: G1822 No. References: 13
Title: ACTIVATION OF MINERALOCORTICOID *AGONIST* AND ANTAGONIST SPECIFIC
RECEPTORS FROM RAT-KIDNEY
Author(s): AGARWAL MK; KALIMI M
Corporate Source: CTR UNIV CORDELIERS, 15 RUE ECOLE MED/F-75270 PARIS
06//FRANCE//; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT
PHYSIOL/RICHMOND//VA/23298
Journal: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, V143,
N1, P398-402
Language: ENGLISH Document Type: ARTICLE

7/3/11
DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

07881290 Genuine Article#: F9115 No. References: 185
Title: THE DESIGN AND USE OF SEX-STEROID ANTAGONISTS
Author(s): RAYNAUD JP; OJASOO T
Corporate Source: ROUSSEL UCLAF, 35 BD INVALID/F-75007 PARIS//FRANCE/
Journal: JOURNAL OF STEROID BIOCHEMISTRY, 1986, V25, N5B, P811-833
Language: ENGLISH Document Type: REVIEW, BIBLIOGRAPHY

7/3/12
DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

07698463 Genuine Article#: F1954 No. References: 58
Title: ROLE OF EPITHELIAL-STROMAL INTERACTIONS IN THE CONTROL OF
GENE-EXPRESSION IN THE PROSTATE - AN HYPOTHESIS
Author(s): TENNISWOOD M
Corporate Source: UNIV OTTAWA, DEPT BIOCHEM/OTTAWA K1H 8M5/ONTARIO/CANADA/
Journal: PROSTATE, 1986, V9, N4, P375-385

Language: ENGLISH Document Type: ARTICLE

7/3/13
DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

07607035 Genuine Article#: E6130 No. References: 682
Title: THE ELECTRICAL DIMENSION OF CELLS - THE CELL AS A MINIATURE
ELECTROPHORESIS CHAMBER
Author(s): DELOOF A
Corporate Source: CATHOLIC UNIV LEUVEN, INST ZOOL/B-3000 LOUVAIN//BELGIUM/
Journal: INTERNATIONAL REVIEW OF CYTOLOGY, 1986, V104, P251-352
Language: ENGLISH Document Type: REVIEW, BIBLIOGRAPHY

7/3/14
DIALOG(R)File 434:SciSearch(R) Cited Ref Sci
(c) 1998 Inst for Sci Info. All rts. reserv.

07193257 Genuine Article#: A6254 No. References: 37.
Title: PROSTATE-CANCER - BIOLOGICAL BASIS FOR THE INCLUSION OF AN
ANTIANDROGEN IN THE TREATMENT
Author(s): RAYNAUD JP; COUSSEDIERE D; MOGUILEWSKY M; POTTIER J; LABRIE F
Corporate Source: ROUSSEL UCLAF/F-75007 PARIS//FRANCE//; CHU LAVAL/QUEBEC
CITY G1V 4G2/QUEBEC/CANADA/
Journal: BULLETIN DU CANCER, 1986, V73, N1, P36-46
Language: FRENCH Document Type: ARTICLE
?s tata box

S8 0 TATA BOX
?ds

Set	Items	Description
S1	0	ALLYLHYDROCARBON RECEPTO?
S2	0	ALLYLHYDROCARBON RECEPTO?
S3	1	ARNT
S4	1847	HORMONE RECEPTOR?
S5	52	S4 AND AGONIST
S6	14	S5 AND ESTROGEN
S7	14	RD (unique items)
S8	0	TATA BOX

?logoff

29dec00 15:38:05 User259980 Session D61.3
\$11.98 0.918 DialUnits File434
\$52.50 14 Type(s) in Format 3
\$3.75 1 Type(s) in Format 9
\$56.25 15 Types
\$68.23 Estimated cost File434
\$0.35 TYMNET
\$68.58 Estimated cost this search
\$69.29 Estimated total session cost 1.094 DialUnits

Status: Signed Off. (7 minutes)